Haisco Pharmaceutical Group (002653.SZ) and Nuvectis have signed authorization license agreements for HSK42360 and HSK39297.

Haisco Pharmaceutical Group (002653.SZ) announced that the company has recently signed an exclusive license agreement with American company Nuvectis Pharma, Inc. (hereinafter referred to as "Nuvectis"). This agreement grants Nuvectis the exclusive rights to develop, manufacture, and commercialize the HSK42360 project (a BRAF inhibitor) globally outside of the Greater China region, as well as the exclusive rights to develop, manufacture, and commercialize the HSK39297 project (a CFB inhibitor) globally outside of the Greater China, Southeast Asia, and India regions. As part of the licensing transaction, the company will receive licensing fees for the HSK42360 and HSK39297 projects from Nuvectis (including a $40 million upfront payment, milestone payments, and additional milestone payments of up to $1.421 billion), as well as sales royalties. HSK42360 is a novel BRAF paradoxical breaker inhibitor developed independently by the company. It can inhibit BRAF V600X mutations while also blocking the formation of BRAF dimers, thereby overcoming the acquired resistance issues seen with first-generation BRAF inhibitors in the treatment of various cancers. This molecule has good central nervous system penetration and has demonstrated strong potential therapeutic advantages in primary brain tumors and brain metastases. Currently, HSK42360 is undergoing phase I clinical trials. HSK39297 is a highly efficient selective complement factor B (FB) small molecule inhibitor developed independently by the company. By inhibiting FB activity, it blocks the activation of the alternative pathway (AP) and the amplification cycle of the complement system, thereby inhibiting the activity of the entire complement pathway. The aim is to treat various diseases mediated by abnormal complement activation. Currently, HSK39297 has submitted a new drug application (NDA) for the treatment of PNH indications in China, and is undergoing phase II clinical trials in patients with lupus nephritis and phase III clinical trials in patients with primary IgA nephropathy.